Prevention of infection in cancer patients

Supportive Care in Cancer: A Handbook for Oncologists

Volumn , Issue , 1999, Pages 129-154

  Schimpff, Stephen C ^a  

^a UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0012444507     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (74)

1. Alavi JB, Root RK, Djerassi I, et al. A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. N Engl J Med 1977; 295:706-711.
2. Herzig RH, Herzig GP, Graw RG Jr, et al. Successful granulocyte transfusion therapy for gram-negative septicemia. A prospectively randomized controlled study. N Engl J Med 1977; 296:701-705.
3. Strauss RG, Connett JE, Gale RP, et al. A controlled trial of prophylactic granulocyte transfusions during initial induction chemotherapy for acute myelogenous leukemia. N Engl J Med 1981; 305:597-638.
4. Clift RA, Sanders JE, Thomas ED. Granulocyte transfusions for the prevention of infection in patients receiving bone-marrow transplants. N Engl J Med 1978; 298: 1052-1057.
5. Schiffer CA. Granulocyte transfusions: an overlooked therapeutic modality. Transfusion Med Rev 1990; 4:2-7.
6. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocytemacrophage colony-stimulating factor. N Engl J Med 1992; 327:99-106.
7. Roilides E, Walsh TJ, Pizzo PA, Rubin M. Granulocyte colony-stimulating factor enhances the phagocytic and bacterial activity of normal and defective human neutrophils. J Infect Dis 1991; 163:579-583.
8. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer [see comments]. N Engl J Med 1991; 325:164-170.
9. Brandt SJ, Peters WP, Atwater SK, et al. Effect of recombinant human granulocytemacrophage colony-stimulating factor on hematopoietic reconstitution after highdose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988; 318:869-876.
10. Peters WP. Use of cytokines during prolonged neutropenia associated with autologous bone marrow transplantation (see comments) Rev Infect Dis 1991; 13:993-996.
11. Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324:1773-1778.
12. Capizzi RL, Schefler BJ, Schein PS. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer 1993; 72:3495-3501.
13. Schimpff SC, Young VM, Greene WH, Vermeulen GD, Moody MR, Wiernik PH. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med 1972; 77:707-714.
14. Doebbeling BN, Stanley GL, Sheetz CT, et al. Comparative efficacy of alternative hand-washing agents in reducing nosocomial infections in intensive care units. N Engl J Med 1992; 327:88-93.
15. Remington JS, Schimpff SC. Please don’t eat the salads. N Engl J Med 1981; 304: 433-435.
16. Nauseef WM, Maki DG. A study of the value of simple protective isolation in patients with granulocytopenia. N Engl J Med 1981; 304:448-453.
17. Schimpff SC, Greene WH, Young VM, et al. Infection prevention in acute nonlymphocytic leukemia. Laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Intern Med 1975; 82:351-358.
18. Hasegawa H, Horiuchi S. Application of simplified bioclean apparatuses for treatment of acute leukemia. Jpn J Clin Oncol 1983; 13(suppl 1):133-142.
19. Murillo J, Schimpff SC, Brouillet MD. Axillary lesions in patients with acute leukemia: evaluation of a preventive program. Cancer 1979; 43:1493-1496.
20. Wade JC, Newton B, McLaren C. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation. Ann Intern Med 1982; 96:265.
21. Wade JC, Newton B, Flourney N, et al. Oral acyclovir for prevention of herpes simplex reactivation after marrow transplantation. Ann Intern Med 1984; 100:823-828.
22. Bustamante CI, Wade JC. Herpes simplex virus infection in the immunocompromised cancer patient. J Clin Oncol 1991; 10:1903-1915.
23. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977; 297:1419-1426.
24. Dekker AW, Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leuke mia: A comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med 1987; 106:7-12.
25. Karp JE, Merz WG, Hendricksen C, et al. Oral norfloxacin for prevention of gramnegative bacterial infections in patients with acute leukemia and granulocytopenia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1987; 106: 1-7.
26. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. Ann Intern Med 1991; 115:7-12.
27. Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996; 23:795-805.
28. The International Antimicrobial Therapy Project Group of the EORTC. Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. JAMA 1994; 272:1183-1189.
29. Cometto A, Calandra T, Bille J, et al. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia (letter). N Engl J Med 1994; 330:1240-1241.
30. Klastersky J. Prevention and therapy of fungal infections in cancer patients. A review of recently published information. Support Care Cancer 1995; 3:393-401.
31. Wade JC, Schimpff SC, Hargadon MT, Fortner CL, Young VM, Wiernik PH. A comparison of trimethoprim-sulfamethoxazole plus nystatin with gentamicin plus nystatin in the prevention of infections in acute leukemia. N Engl J Med 1981; 304: 1057-1062.
32. Hann IM, Prentice HG, Corringham R, et al. Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. Lancet 1982; 1:826-829.
33. Owens NJ, Nightingale CH, Schweizer R, Schauer PK, Dekker PT, Quintiliani R. Prophylaxis of oral candidiasis with clotrimazole troches. Arch Intern Med 1984; 144:290-293.
34. Drouhet E, DuPont B. Evolution of antifungal agents: past present and future. Rev Infect Dis 1987; 9(suppl 1):S4-S14.
35. Walsh TJ, Lee J, Aoki S, et al. Experimental basis for use of fluconazole for preventive or early treatment of disseminated candidiasis in granulocytopenic hosts. Rev Infect Dis 1990; 12(suppl 3):S307-S317.
36. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-851.
37. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole (see comments). N Engl J Med 1991; 325:1274-1277.
38. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebocontrolled, double-blind, multicenter trial. Ann Intern Med 1993; 118:495-503.
39. Tam JY, Blume KG, Prober CG. Prophylactic fluconazole and Candida krusei infections (letter). N Engl J Med 1992; 326:891.
40. Perfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992; 165:891-897.
41. Rousey SR, Russler S, Gottlieb M, et al. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation. Am J Med 1991; 91:484.
42. Cushing D, Bustamante C, Devlin A. Aspergillus Infection Prophylaxis: Amphotericin- B Nose Spray, A Double-Blind Trial (abstr). Interscience Conference on Antimicrobial Agents and Chemotherapy 1991:737.
43. Jeffrey GM, Beard ME, Ikram RB, et al. Intranasal amphotericin B reduces the frequency of invasive aspergillosis in neutropenic patients. Am J Med 1991; 90: 685-692.
44. Tenney JH, Moody MR, Newman KA, et al. Adherent microorganisms on lumenal surfaces of long-term intravenous catheters: importance of Staphylococcus epidermidis in patients with cancer. Arch Intern Med 1986; 146:1949-1954.
45. Newman KA, Reed WP, Schimpff SC, et al. Hickman catheters in association with intensive cancer chemotherapy. Support Care Cancer 1993; 1:92-97.
46. Rackoff WR, Weiman J, Jakobowski, et al. A randomized, controlled trial of the efficacy of a heparin and vancomycin solution in preventing central venous catheter infections in children. J Pediatr 1995; 127:147-151.
47. Pizzo PA, Schimpff SC. Strategies for the prevention of infection in the myelosuppressed or immunosuppressed cancer patient. Cancer Treat Rep 1983; 67:223-234.
48. Gershon AA, LaRussa P, Hardy I, Steinberg S, Silverstein S. Varicella vaccine: the American experience. J Infect Dis 1992; 166(suppl 1):S63-S68.
49. Hardy IB, Gershon A, Steinberg S, LaRussa P. NIAID Collaborative Varicella Vaccine Study Group. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. N Engl JMed 1991; 325:1545-1550.
50. Gershon AA, Steinberg SP, LaRussa P, et al. Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis 1988; 158:132-137.
51. Weibel R, Neff BJ, Kuter BJ, et al. Live attenuated varicella virus vaccine: efficacy trial in healthy children. N Engl J Med 1984; 310:1409-1415.
52. Remington JS, McLeod R. Toxoplasmosis. In: Gorbach SL, Bartlett JG, eds. Infectious Diseases. 1st ed. Philadelphia: WB Saunders, 1992:1328-1342.
53. Linnan MJ, Mascola L, Lou XD, et al. Epidemic listeriosis associated with Mexicanstyle cheese. N Engl J Med 1988; 319:823-828.
54. Schuchat A, Deaver KA, Wenger JD, et al. Role of foods in sporadic listeriosis. I. Case-control study of dietary risk factors. JAMA 1992; 267:2041-2045.
55. Pinner RW, Schuchat A, Swaminathan B, et al. Role of foods in sporadic listeriosis. II. Microbiologic and epidemiologic investigation. JAMA 1992; 267:2046-2050.
56. Nightingale SL. Efforts to prevent foodborne listeriosis. JAMA 1992; 268:180.
57. Schmidt GM. Prophylaxis of cytomegalovirus infection after bone marrow transplantation. Semin Oncol 1992; 19:20-26.
58. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl JMed 1991; 325:1601-1607.
59. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope- Stanford-Syntex CMV Study Group (see comments). N Engl J Med 1991; 324: 1005-1011.
60. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118:173-178.
61. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 1993; 118:179-184.
62. Reusser P, Gambertoglio JG, Lilleby K, Meyers JD. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis 1992; 166:473-479.
63. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992; 257:238-241.
64. Riddell SR, Reusser P, Greenberg PD. Cytotoxic T cells specific for cytomegalovirus a potential therapy for immunocompromised patients. Rev Infect Dis 1991; 13(suppl 11):S966-S973.
65. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled trial. N Engl J Med 1988; 319: 902-907.
66. Sullivan KM, Kopecky KJ, Jocom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323:705-712.
67. Wolff SN, Fay JW, Herzig RH, et al. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group. Ann Intern Med 1993; 18:937-942.
68. Schimpff SC. Infection in bone marrow transplantation: a model for examining predisposing factors to infection in cancer patients. In: Schimpff SC, Klastersky J, eds. Infectious Complications in Bone Marrow Transplantation. Recent Results in Cancer Research 132. Heidelberg: Springer-Verlag, 1993:15-34.
69. Donowitz GR. Infections in bone marrow transplant recipients. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and Practice of Infectious Diseases. Quarterly Update 12. New York: Churchill Livingstone, 1992:3-12.
70. Momin F, Chandrasekar PH. Antimicrobial prophylaxis in bone marrow transplantation. Ann Intern Med 1995; 123:205-215.
71. Schmidt GM. Treatment and prophylaxis of cytomegalovirus infection after bone marrow transplantation. In: Schimpff SC, Klastersky J, eds. Infectious Complications in Bone Marrow Transplantation. Recent Results in Cancer Research 132. Heidelberg: Springer-Verlag, 1993:161-174.
72. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Preface to the 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1997; 25(suppl 3):S299-S312.
73. USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. Clin Infect Dis 1997; 25(suppl 3):S313-S335.
74. Joshi JH, Schimpff SC. Infections in the compromised host. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and Practice of Infectious Diseases. 2nd ed. New York: John Wiley & Sons, 1984:1664.